These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3536 related items for PubMed ID: 11691814

  • 1. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 2. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
    Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A.
    Clin Cancer Res; 1999 Feb 01; 5(2):445-54. PubMed ID: 10037196
    [Abstract] [Full Text] [Related]

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 01; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May 01; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 5. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
    Ohta K, Yamaguchi Y, Shimizu K, Miyahara E, Toge T.
    Anticancer Res; 2002 May 01; 22(5):2597-606. PubMed ID: 12529970
    [Abstract] [Full Text] [Related]

  • 6. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Katsuda M, Miyazawa M, Yamaue H.
    Int J Oncol; 2007 Oct 01; 31(4):931-9. PubMed ID: 17786327
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N.
    J Immunother; 2001 Oct 01; 24(3):205-11. PubMed ID: 11394497
    [Abstract] [Full Text] [Related]

  • 8. Generation of CMRF-44+ monocyte-derived dendritic cells: insights into phenotype and function.
    Vuckovic S, Fearnley DB, Mannering SI, Dekker J, Whyte LF, Hart DN.
    Exp Hematol; 1998 Dec 01; 26(13):1255-64. PubMed ID: 9845382
    [Abstract] [Full Text] [Related]

  • 9. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
    Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY.
    Cancer Res; 2001 Apr 01; 61(7):3096-104. PubMed ID: 11306493
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ, Yao K, Yu CJ, Chen X, Lu MP, Sun H, Li BZ, Ding CN, Zhou F.
    Auris Nasus Larynx; 2006 Dec 01; 33(4):441-6. PubMed ID: 16934422
    [Abstract] [Full Text] [Related]

  • 11. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P, Aigner M, Schirrmacher V.
    Int J Oncol; 2011 Jun 01; 38(6):1719-29. PubMed ID: 21424118
    [Abstract] [Full Text] [Related]

  • 12. Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes.
    Suzuki H, Katayama N, Ikuta Y, Mukai K, Fujieda A, Mitani H, Araki H, Miyashita H, Hoshino N, Nishikawa H, Nishii K, Minami N, Shiku H.
    Am J Hematol; 2004 Apr 01; 75(4):179-89. PubMed ID: 15054806
    [Abstract] [Full Text] [Related]

  • 13. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM, Zheng SE, Bader A, Yao HP, Wu NP, Altmeyer P, Brockmeyer NH, Jin J.
    Eur J Med Res; 2008 Jan 23; 13(1):7-14. PubMed ID: 18226991
    [Abstract] [Full Text] [Related]

  • 14. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W.
    Cancer Res; 1998 Feb 15; 58(4):732-6. PubMed ID: 9485028
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.
    Clin Immunol; 2009 Nov 15; 133(2):184-97. PubMed ID: 19664962
    [Abstract] [Full Text] [Related]

  • 16. [In vitro inducing differentiation of bone marrow mononuclear cells of chronic myeloid leukemia].
    Wu CY, Zhang LS, Zhang YF, Chai Y, Yi LC, Song FX.
    Ai Zheng; 2005 Apr 15; 24(4):425-31. PubMed ID: 15820064
    [Abstract] [Full Text] [Related]

  • 17. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J, Wu JH, Bouganim N, Galipeau J.
    Cancer Res; 2004 Dec 15; 64(24):8795-9. PubMed ID: 15604233
    [Abstract] [Full Text] [Related]

  • 18. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X, Jun DY, Thomas AM, Huang X, Huang LQ, Mautner J, Mo W, Robbins PF, Pardoll DM, Jaffee EM.
    Cancer Res; 2005 Feb 01; 65(3):1079-88. PubMed ID: 15705910
    [Abstract] [Full Text] [Related]

  • 19. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.
    Avigan D, Wu Z, Gong J, Joyce R, Levine J, Elias A, Richardson P, Milano J, Kennedy L, Anderson K, Kufe D.
    Clin Cancer Res; 1999 Oct 01; 5(10):2735-41. PubMed ID: 10537336
    [Abstract] [Full Text] [Related]

  • 20. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.
    Hinkel A, Tso CL, Gitlitz BJ, Neagos N, Schmid I, Paik SH, deKernion J, Figlin R, Belldegrun A.
    J Immunother; 2000 Jan 01; 23(1):83-93. PubMed ID: 10687141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 177.